Elanco (ELAN) director granted stock and deferred unit awards as compensation

Rhea-AI Filing Summary

Anand Kapila K reported acquisition or exercise transactions in this Form 4 filing.

Elanco Animal Health director Anand K. Kapila received equity compensation, not making any open-market trades. On May 21, 2026, he was granted 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award for non-employee directors. Both awards were recorded at $0.00 per share, reflecting stock-based compensation rather than a purchase. After these grants, the filing reports his direct ownership of Elanco common stock at 111,847 shares.

Insights

Equity compensation analyst

Routine director equity grants with no open-market buying or selling.

Anand K. Kapila, a non-employee director of Elanco Animal Health, received stock-based compensation rather than trading in the market. He was awarded 12,196 deferred stock units and 4,678 restricted stock units on May 21, 2026.

These are labeled as annual and pro-rated equity awards to non-employee Board members, granted at $0.00 per share. That indicates standard director compensation, not a cash outlay by the insider or a capital-raising event for the company.

Following the awards, the filing shows Kapila holding 99,651 Elanco common shares directly. Because there are no open-market purchases or sales and no derivative exercises, the informational value for sentiment is limited and the event appears routine.

Insider Trade Summary

Net Buyer: 16,874 shares

Net Buy 2 txns

Insider Anand Kapila K

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,678	$0.00	$0.00
Grant/Award	Common Stock	12,196	$0.00	$0.00

Holdings After Transaction: Common Stock — 111,847 shares (Direct)

Footnotes (2)

1. F1. Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors.
2. F2. Grant of restricted stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

Key Figures

Deferred stock units granted: 12,196 units Restricted stock units granted: 4,678 units Price per share for grants: $0.00 per share +2 more

5 metrics

Deferred stock units granted 12,196 units Grant of deferred stock units on May 21, 2026

Restricted stock units granted 4,678 units Grant of restricted stock units on May 21, 2026

Price per share for grants $0.00 per share Equity awards recorded as compensation, not purchases

Shares owned after transaction 99,651 shares Direct common stock ownership following latest grant

Number of acquisition transactions 2 transactions Both coded A as grants or awards

Key Terms

deferred stock units, restricted stock units, non-employee members of the Issuer's Board of Directors, Grant, award, or other acquisition

4 terms

deferred stock units financial

"Grant of deferred stock units as a pro-rated annual equity award"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

restricted stock units financial

"Grant of restricted stock units as an annual equity award"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

non-employee members of the Issuer's Board of Directors regulatory

"annual equity award to each of the non-employee members of the Issuer's Board of Directors"

Grant, award, or other acquisition regulatory

"transaction code description is Grant, award, or other acquisition"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 05/26/2026 - 04:43 PM Learn about SEC filing dates

FAQ

What did Elanco (ELAN) director Anand K. Kapila report in this Form 4?

He reported receiving stock-based compensation awards, not market trades. On May 21, 2026, Kapila was granted deferred stock units and restricted stock units as equity awards for his service as a non-employee director on Elanco’s Board of Directors.

How many Elanco (ELAN) shares were granted to Anand K. Kapila?

Kapila was granted 12,196 deferred stock units and 4,678 restricted stock units. These units represent promises of Elanco common stock, typically delivered over time under the company’s director compensation programs, rather than immediate cash or open-market stock purchases.

What was the price per share for Anand K. Kapila’s Elanco equity awards?

Both awards were recorded at $0.00 per share. This reflects that they are compensation grants of equity, not shares bought in the market, so Kapila did not pay cash to acquire these units at the time of the Form 4 transactions.

How many Elanco (ELAN) shares does Anand K. Kapila hold after these grants?

After the May 21, 2026 equity awards, the Form 4 reports Kapila directly owning 99,651 shares of Elanco common stock. This figure incorporates the reported non-derivative holdings following the latest grant of restricted stock units to the non-employee director.

Are Anand K. Kapila’s Elanco transactions open-market buys or sells?

No, the transactions are classified as acquisitions from grants or awards, with code A. The Form 4 shows they are deferred stock units and restricted stock units granted as director compensation, not open-market purchases or sales of Elanco shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anand Kapila K

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS INDIANA 46221

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A		4,678(1)	A	$0	99,651	D
Common Stock	05/21/2026		A		12,196(2)	A	$0	111,847	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors.

2. Grant of restricted stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Kapila K. Anand	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)